Hi Scott

I have read that about 13-40% of all non-IPF ILD will develop a progressive fibrosing phenotype. Here’s the link to the American Thoracic Society’s Progressive Fibrosing Interstitial Lung Disease Primer. Everything you need to know in terms of different types, risk factors, management etc is there. It’s the best thing I’ve found on… Read more

Hi John,

Ground glass opacities usually represent inflammation (and a few other things) whereas true fibrosis is defined by distinct features such as honeycombing, traction bronchiectasis, reticulations. So in your case it seems you have inflammatory changes caused by Covid and they will hopefully decrease. In some patients these changes… Read more

I think the understanding is that there is a genetic predisposition to IPF. I think familial IPF provides evidence for this. Research indicates that both genetic predisposition and environmental factors contribute to the risk of IPF and other idiopathic interstitial pneumonias.

 

 

 

Hi Pete,

Japanese scientists published a research article in early 2022 on the therapeutic effects of eperisone (muscle relaxant) on pulmonary fibrosis, showing that it is more effective in supressing fibroblast activity than current antifibrotic medication (pirfenidone and nintedanib). Eperisone also showed less adverse side effects.… Read more

Hi Joe,

I think your pulmonologist diagnosed you with IPF because your CT scan showed a pattern of UIP (usual interstitial pneumonia) which is associated with IPF. That means that the distribution (subpleural, basal and bilateral) and features (reticulation) of scars point to UIP. I would add, as others already have, that there is absence… Read more